Evaluating the survival outcomes in clinical node stage 2 and 3 breast cancer patients with negative sentinel lymph node biopsy after neoadjuvant chemotherapy: sentinel lymph node biopsy alone vs. axillary lymph node dissection.

Front Oncol · 2025 · PMC12129956 · PMID 40463878

Europe PMC DOI

hedged sentence

0.9720

closest p · 19.4× alpha

0.9720

boldest claim

The sentences

did not reach statistical significancep=0.972not close (p > 0.1)

Regarding overall survival (OS), while a slight difference was noted—94.2% in the SNB alone group versus 87.6% in the SNB+ALND group—this difference did not reach statistical significance (p=0.972, Figure 2c ).

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.